BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Merck Group announced on Wednesday, March 24, that it has assigned a new chief financial officer. The company picked Caroline Litchfield to be Robert Davis’s replacement and she will assume her post starting April 1.
Litchfield’s new appointment at the company
As per Reuters, Litchfield has been working for Merck since 1990. At that time, she joined the company as part of its unit in the U.K. Prior to her new assignment as CFO this year, she was in charge of Merck’s treasury, tax and investor relations.
She has also worked in the financial operations section for Merck’s Human Health. This unit is the pharmaceutical firm’s largest business to date.
In any case, she will be succeeding Rob Davis, who will leave his post as CFO. He will be taking over as the company’s new chief executive officer as the current CEO, Ken Frazier, already announced last month that he is retiring in June.
Litchfield’s expected contribution as the new CFO
The new assignments of chief officers also come as Merck is aiming for transformation. It wanted to diversify its offerings and go beyond the immuno-oncology business development. It was mentioned that Litchfield would be a big help in this transition as she takes on part of the responsibilities for this plan.
“Caroline’s appointment as our next CFO is the result of a combination of factors and most importantly, Caroline’s financial expertise, remarkable track record, and leadership as well as our commitment to developing talent and our succession planning for leadership roles,” Kenneth C. Frazier said in a press release.
Davis added, “Caroline’s passion for Merck’s mission and for the patients we serve guides every decision that she makes." He said he is also looking forward to working with Caroline and "to benefit from her expertise and leadership as we chart the course for Merck in the months and years ahead.”
In response to the warm welcome from her colleagues, Caroline Litchfield said that she is very honored to serve Merck as the new CFO. She went on to say that her assignment is even more meaningful as it comes at such a pivotal time when the company is transitioning to improve lives.
